Fycompa approved for partial onset seizures
The FDA has approved Fycompa tablets to treat partial onset seizures in individuals aged 12 years and older who have epilepsy,
The FDA has approved Fycompa tablets to treat partial onset seizures in individuals aged 12 years and older who have epilepsy,
The FDA has approved bosutinib (Bosulif, Pfizer) for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML, who are resistant to or who cannot tolerate other therapies.
The FDA has approved tbo-filgrastim to treat neutropenia in patients with nonmyeloid malignancies, who receive myelosuppressive chemotherapy.
The first pediatric form of the cancer drug everolimus has been sanctioned to treat rare brain tumors in children aged 1 year and older.
Linzess sanctioned for constipation that does not respond to conventional treatment.
Stribild, a combination drug that only has to be taken once a day, interferes with enzymes that are needed for HIV to multiply.
The FDA has approved ziv-aflibercept (Zaltrap, Sanofi-Aventis) in combination with a FOLFIRI regimen for adults with advanced metastatic colorectal cancer.
Zetonna is a nasal aerosol approved to treat both ocular and nasal symptoms associated with seasonal allergic rhinitis (SAR), and nasal symptoms associated with perennial allergic rhinitis (PAR) in adults and adolescents aged >12 years.
The FDA has approved the oral contraceptive, Natazia, to treat women with heavy menstrual bleeding that is not caused by a diagnosed condition of the uterus.
Surfaxin (lucinactant) is indicated for the prevention of respiratory distress syndrome, a breathing disorder that affects premature infants.